|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Celgene_Corporation
|
|
gptkbp:acquisition
|
gptkb:Impact_Biomedicines
gptkb:Celgene_Corporation
gptkb:2019
gptkb:Juno_Therapeutics
gptkb:Myokardia
Celgene's acquisition of Receptos
|
|
gptkbp:ceo
|
gptkb:Mark_J._Alles
|
|
gptkbp:clinical_trial
|
gptkb:Luspatercept
gptkb:drug
Abecma
Abecma (Multiple Myeloma Treatment)
CART-cell therapy (Cancer Treatment)
CC-122
CC-122 (Immunomodulatory Drug)
CC-220
CC-220 (Immunomodulatory Drug)
CC-486
CC-486 (Oral Azacitidine)
CC-90009
CC-90009 (Immunomodulatory Drug)
CC-92480
CC-92480 (Immunomodulatory Drug)
Luspatercept (Anemia Treatment)
Ozanimod
Ozanimod (Ulcerative Colitis Treatment)
|
|
gptkbp:employees
|
7,000 (2019)
|
|
gptkbp:founded
|
gptkb:1986
|
|
gptkbp:founder
|
gptkb:Robert_J._Hugin
|
|
gptkbp:headquarters
|
gptkb:Summit,_New_Jersey
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CELG
|
|
gptkbp:industry
|
gptkb:Company
|
|
gptkbp:market_cap
|
$74 billion (2019)
|
|
gptkbp:parent_company
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:partnership
|
gptkb:Bristol-Myers_Squibb
gptkb:Janssen_Pharmaceuticals
gptkb:Amgen
gptkb:Abb_Vie
|
|
gptkbp:products
|
gptkb:Revlimid
gptkb:Pomalyst
Otezla
|
|
gptkbp:research_focus
|
gptkb:healthcare_organization
inflammatory diseases
|
|
gptkbp:revenue
|
$16 billion (2019)
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:subsidiary
|
gptkb:Celgene_Corporation
gptkb:Celgene_Cellular_Therapeutics
gptkb:Celgene_International_Sàrl
|
|
gptkbp:symbol
|
gptkb:CELG
|